At JP Morgan this year, pharmaphorum Editor in Chief Jonah Comstock spoke with Jeff Fischer, president of Longhorn Vaccines ...

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication ...

DCT approaches in Japan typically involve partnerships among multiple satellite hospitals. Three main models aim to boost ...

The TxGemma models are – as the name suggests – an offshoot of Google's Gemma family of open-source, generative AI (GenAI) ...

An even greater challenge is their need for external investment. During the early stages of development, in order to progress ...

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's ...

The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...

The IMPACCT Real World Evidence Summit is back, offering the opportunity to bring together 50+ pharma RWE decision makers to ...

Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to ...

Novartis said that the latest round of job losses is a result of a change in focus for its cardiovascular teams as they lower the emphasis on Entresto and devote more resources to its twice-yearly ...

February saw a flurry of significant hires in the agency world, with several key players making strategic appointments to bolster their leadership teams. We’ve also included consultancy and investor ...